COVID-19 VaccinE Response in Rheumatology Patients

NCT05080218 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

841

Enrollment

OTHER

Sponsor class

Conditions

Rheumatoid Arthritis
Psoriatic Arthritis
Spondylarthritis

Interventions

DRUG: Upadacitinib
DRUG: Abatacept
DRUG: Secukinumab
DRUG: Tofacitinib
DRUG: TNF Inhibitor
DRUG: Canakinumab Injection
DRUG: Baricitinib
DRUG: Ixekizumab

Sponsor

Jeffrey Curtis

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]